JP2015509368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509368A5 JP2015509368A5 JP2014558920A JP2014558920A JP2015509368A5 JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5 JP 2014558920 A JP2014558920 A JP 2014558920A JP 2014558920 A JP2014558920 A JP 2014558920A JP 2015509368 A5 JP2015509368 A5 JP 2015509368A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603622P | 2012-02-27 | 2012-02-27 | |
| US61/603,622 | 2012-02-27 | ||
| PCT/US2013/027580 WO2013130381A1 (en) | 2012-02-27 | 2013-02-25 | Cx3cr1-binding polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015509368A JP2015509368A (ja) | 2015-03-30 |
| JP2015509368A5 true JP2015509368A5 (enExample) | 2015-05-07 |
| JP6101715B2 JP6101715B2 (ja) | 2017-03-22 |
Family
ID=47884535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558920A Active JP6101715B2 (ja) | 2012-02-27 | 2013-02-25 | Ｃｘ３ｃｒ１結合ポリペプチド |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US9035029B2 (enExample) |
| EP (2) | EP2820046B1 (enExample) |
| JP (1) | JP6101715B2 (enExample) |
| KR (1) | KR102008136B1 (enExample) |
| CN (3) | CN104245735B (enExample) |
| AP (1) | AP2014007791A0 (enExample) |
| AR (1) | AR090158A1 (enExample) |
| AU (1) | AU2013226340B2 (enExample) |
| CA (1) | CA2862182A1 (enExample) |
| CL (1) | CL2014002072A1 (enExample) |
| EA (1) | EA028183B1 (enExample) |
| EC (1) | ECSP14020402A (enExample) |
| GE (1) | GEP201706773B (enExample) |
| IL (3) | IL291571B2 (enExample) |
| IN (1) | IN2014DN05756A (enExample) |
| MD (1) | MD4548C1 (enExample) |
| MX (1) | MX349192B (enExample) |
| NZ (1) | NZ627260A (enExample) |
| PE (1) | PE20141859A1 (enExample) |
| PH (2) | PH12021553014A1 (enExample) |
| SG (1) | SG11201405283SA (enExample) |
| TN (1) | TN2014000360A1 (enExample) |
| TW (1) | TWI598361B (enExample) |
| UA (1) | UA115781C2 (enExample) |
| UY (1) | UY34644A (enExample) |
| WO (1) | WO2013130381A1 (enExample) |
| ZA (3) | ZA201405021B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9556273B2 (en) | 2010-03-29 | 2017-01-31 | Vib Vzw | Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages |
| US9101674B2 (en) | 2010-03-29 | 2015-08-11 | Vib Vzw | Targeting and in vivo imaging of tumor-associated macrophages |
| PH12021553014A1 (en) | 2012-02-27 | 2022-09-05 | Ablynx Nv | Cx3cr1-binding polypeptides |
| EP3035970A1 (en) * | 2013-08-21 | 2016-06-29 | Boehringer Ingelheim International GmbH | Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease |
| RU2609627C2 (ru) * | 2014-09-26 | 2017-02-02 | Закрытое Акционерное Общество "Биокад" | Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh |
| BR112018001161A2 (pt) | 2015-07-23 | 2018-09-18 | Inhibrx Lp | proteínas de fusão de ligação a gitr multiespecíficas e multivalentes |
| SG11201805422WA (en) * | 2016-01-11 | 2018-07-30 | Inhibrx Inc | Multivalent and multispecific ox40-binding fusion proteins |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| MA43816A (fr) * | 2016-03-08 | 2018-11-28 | Maverick Therapeutics Inc | Protéines de liaison inductibles et méthodes d'utilisation |
| AU2017368518B2 (en) | 2016-11-29 | 2023-05-18 | National Center Of Neurology And Psychiatry | Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases |
| WO2018134815A2 (en) * | 2017-01-17 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| IL317013A (en) | 2017-09-08 | 2025-01-01 | Takeda Pharmaceuticals Co | Binding proteins are activated under limited conditions |
| BR112021002164A2 (pt) | 2018-08-13 | 2021-08-03 | Inhibrx, Inc. | polipeptídeos de ligação a ox40 e usos dos mesmos |
| EP4592313A3 (en) | 2019-03-05 | 2025-11-19 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| CN110675421B (zh) * | 2019-08-30 | 2022-03-15 | 电子科技大学 | 基于少量标注框的深度图像协同分割方法 |
| US20230233701A1 (en) * | 2020-06-02 | 2023-07-27 | Children's Medical Center Corporation | Nanobody (vhh) conjugates and uses there of |
| US20240109954A1 (en) * | 2021-02-01 | 2024-04-04 | The General Hospital Corporation | Fc-enhanced antibodies for prevention and treatment of ebola virus infection |
| TW202246334A (zh) * | 2021-02-02 | 2022-12-01 | 美商美國禮來大藥廠 | Gitr拮抗劑及其使用方法 |
| JP2025525566A (ja) | 2022-07-18 | 2025-08-05 | アブリンクス エン．ヴェー． | Ｃｘ３ｃｒ１結合化合物、その使用及び関連する方法 |
| KR20250126016A (ko) | 2022-12-22 | 2025-08-22 | 치오메 바이오사이언스 가부시키가이샤 | 항인간 cx3cr1 항체 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| AU2000273378A1 (en) * | 2000-02-18 | 2001-08-27 | Millennium Pharmaceuticals, Inc. | Therapeutic methods that target fractalkine or cx3cr1 |
| EP1276856A4 (en) | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
| US20020192212A1 (en) * | 2001-03-19 | 2002-12-19 | Toshio Imai | Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine |
| ATE477280T1 (de) | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| JP4123856B2 (ja) | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
| US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003104484A1 (en) | 2002-06-10 | 2003-12-18 | Metabolex, Inc. | Methods of treating and diagnosing diabetes with cx3cr1 modulators |
| WO2004041867A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders |
| EP1578842B1 (en) | 2002-12-31 | 2009-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| PL1639011T3 (pl) | 2003-06-30 | 2009-05-29 | Domantis Ltd | Pegilowane przeciwciała jednodomenowe (dAb) |
| WO2005103684A2 (en) | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cx3c chemokine receptor 1 (cx3cr1) |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| ES2641815T3 (es) | 2004-10-29 | 2017-11-14 | Eisai R&D Management Co., Ltd. | Tratamiento para enfermedades inflamatorias |
| EP1888640B1 (en) | 2005-05-18 | 2012-03-14 | Ablynx N.V. | Improved nanobodies against tumor necrosis factor-alpha |
| US8642330B2 (en) | 2005-08-08 | 2014-02-04 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
| NZ612578A (en) * | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| AU2007293614A1 (en) * | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| WO2009109635A2 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| AU2009237662A1 (en) | 2008-04-17 | 2009-10-22 | Ablynx N.V. | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| HUE042053T2 (hu) | 2008-06-05 | 2019-06-28 | Ablynx Nv | Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére |
| WO2010070394A1 (en) | 2008-12-17 | 2010-06-24 | Universite Pierre Et Marie Curie-Paris Vi | Modulators of the cx3cr1 receptor and therapeutic uses thereof |
| WO2011044377A2 (en) | 2009-10-09 | 2011-04-14 | Cell Point, Llc | Chelator-targeting ligand conjugates for cardiovascular imaging |
| US20110117113A1 (en) * | 2009-10-09 | 2011-05-19 | Gerald Beste | Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them |
| EP2648754A4 (en) * | 2010-12-07 | 2016-02-24 | Philadelphia Health & Educatio | METHOD OF INHIBITING CANCER METASTASES |
| PH12021553014A1 (en) | 2012-02-27 | 2022-09-05 | Ablynx Nv | Cx3cr1-binding polypeptides |
| EP3035970A1 (en) | 2013-08-21 | 2016-06-29 | Boehringer Ingelheim International GmbH | Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease |
-
2013
- 2013-02-25 PH PH1/2021/553014A patent/PH12021553014A1/en unknown
- 2013-02-25 PE PE2014001293A patent/PE20141859A1/es active IP Right Grant
- 2013-02-25 IL IL291571A patent/IL291571B2/en unknown
- 2013-02-25 EP EP13709641.8A patent/EP2820046B1/en active Active
- 2013-02-25 MD MDA20140104A patent/MD4548C1/ro not_active IP Right Cessation
- 2013-02-25 CN CN201380016996.9A patent/CN104245735B/zh active Active
- 2013-02-25 GE GEAP201313583A patent/GEP201706773B/en unknown
- 2013-02-25 UA UAA201410430A patent/UA115781C2/uk unknown
- 2013-02-25 MX MX2014009864A patent/MX349192B/es active IP Right Grant
- 2013-02-25 AU AU2013226340A patent/AU2013226340B2/en active Active
- 2013-02-25 CN CN201810147778.3A patent/CN108610421B/zh active Active
- 2013-02-25 SG SG11201405283SA patent/SG11201405283SA/en unknown
- 2013-02-25 KR KR1020147023938A patent/KR102008136B1/ko active Active
- 2013-02-25 JP JP2014558920A patent/JP6101715B2/ja active Active
- 2013-02-25 WO PCT/US2013/027580 patent/WO2013130381A1/en not_active Ceased
- 2013-02-25 CA CA2862182A patent/CA2862182A1/en not_active Abandoned
- 2013-02-25 EP EP22168124.0A patent/EP4050027A3/en active Pending
- 2013-02-25 IL IL311502A patent/IL311502A/en unknown
- 2013-02-25 US US13/775,307 patent/US9035029B2/en active Active
- 2013-02-25 PH PH1/2014/501912A patent/PH12014501912B1/en unknown
- 2013-02-25 CN CN202210946091.2A patent/CN115925938A/zh active Pending
- 2013-02-25 EA EA201400964A patent/EA028183B1/ru not_active IP Right Cessation
- 2013-02-25 AP AP2014007791A patent/AP2014007791A0/xx unknown
- 2013-02-25 NZ NZ627260A patent/NZ627260A/en unknown
- 2013-02-25 IN IN5756DEN2014 patent/IN2014DN05756A/en unknown
- 2013-02-26 AR ARP130100585A patent/AR090158A1/es active IP Right Grant
- 2013-02-26 TW TW102106771A patent/TWI598361B/zh active
- 2013-02-27 UY UY0001034644A patent/UY34644A/es unknown
-
2014
- 2014-07-09 ZA ZA2014/05021A patent/ZA201405021B/en unknown
- 2014-08-05 CL CL2014002072A patent/CL2014002072A1/es unknown
- 2014-08-07 IL IL234018A patent/IL234018B2/en unknown
- 2014-08-26 TN TNP2014000360A patent/TN2014000360A1/fr unknown
- 2014-09-25 EC ECIEPI201420402A patent/ECSP14020402A/es unknown
-
2015
- 2015-04-09 US US14/682,131 patent/US9458235B2/en active Active
-
2016
- 2016-08-22 US US15/242,639 patent/US9783612B2/en active Active
-
2017
- 2017-09-29 US US15/720,792 patent/US10385134B2/en active Active
-
2019
- 2019-07-09 US US16/505,773 patent/US11384151B2/en active Active
-
2022
- 2022-06-09 US US17/836,473 patent/US12221487B2/en active Active
-
2023
- 2023-09-19 ZA ZA2023/08846A patent/ZA202308846B/en unknown
- 2023-09-19 ZA ZA2023/08845A patent/ZA202308845B/en unknown